loading page

Early COVID-19 XBB.1.5 vaccine effectiveness against hospitalisation among adults targeted for vaccination, VEBIS hospital network, Europe, October 2023--January 2024
  • +27
  • Liliana Antunes,
  • Clara Mazagatos,
  • Iván Martínez-Baz,
  • Reinout Naesens,
  • Maria-Louise Borg,
  • Goranka Petrovic,
  • Terra Fatukasi,
  • Ligita Jancoriene,
  • Ausenda Machado,
  • Beatrix Oroszi,
  • Petr Husa,
  • Mihaela Lazar,
  • Ralf Dürrwald,
  • Jennifer Howard,
  • Aryse Melo,
  • Gloria Pérez-Gimeno,
  • Jesus Castilla,
  • Eva Bernaert,
  • Ausra Dziugyte,
  • Zvjezdana Lovrić Makarić,
  • Margaret Fitzgerald,
  • Auksė Mickienė,
  • Verónica Gómez,
  • Gergő Túri,
  • Lenka Součková,
  • Alexandru Marin,
  • Kristin Tolksdorf,
  • Nathalie Nicolay,
  • Angela Rose,
  • on behalf of the European Hospital Vacci Group
Liliana Antunes
Epiconcept SAS

Corresponding Author:[email protected]

Author Profile
Clara Mazagatos
Instituto de Salud Carlos III
Author Profile
Iván Martínez-Baz
Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica
Author Profile
Reinout Naesens
ZNA
Author Profile
Maria-Louise Borg
Malta Health Promotion and Disease Prevention Directorate
Author Profile
Goranka Petrovic
Hrvatski zavod za javno zdravstvo
Author Profile
Terra Fatukasi
Health Protection Surveillance Centre
Author Profile
Ligita Jancoriene
Vilniaus universitetas Medicinos fakultetas
Author Profile
Ausenda Machado
Instituto Nacional de Saude Doutor Ricardo Jorge
Author Profile
Beatrix Oroszi
Semmelweis Egyetem
Author Profile
Petr Husa
Fakultni nemocnice Brno
Author Profile
Mihaela Lazar
Institutul Cantacuzino
Author Profile
Ralf Dürrwald
Robert Koch-Institut
Author Profile
Jennifer Howard
Epiconcept SAS
Author Profile
Aryse Melo
Instituto Nacional de Saude Doutor Ricardo Jorge
Author Profile
Gloria Pérez-Gimeno
Instituto de Salud Carlos III
Author Profile
Jesus Castilla
Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica
Author Profile
Eva Bernaert
ZNA
Author Profile
Ausra Dziugyte
Malta Health Promotion and Disease Prevention Directorate
Author Profile
Zvjezdana Lovrić Makarić
Hrvatski zavod za javno zdravstvo
Author Profile
Margaret Fitzgerald
Health Protection Surveillance Centre
Author Profile
Auksė Mickienė
Lietuvos sveikatos mokslu universitetas
Author Profile
Verónica Gómez
Instituto Nacional de Saude Doutor Ricardo Jorge
Author Profile
Gergő Túri
Semmelweis Egyetem
Author Profile
Lenka Součková
Fakultni nemocnice Brno
Author Profile
Alexandru Marin
Spitalul Clinic Dr Victor Babes
Author Profile
Kristin Tolksdorf
Robert Koch-Institut
Author Profile
Nathalie Nicolay
European Centre for Disease Prevention and Control
Author Profile
Angela Rose
Epiconcept SAS
Author Profile
on behalf of the European Hospital Vacci Group
no affiliation
Author Profile

Abstract

We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 48% overall, ranging between 68% at 14–29 days and 40% at 60–105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE >70% in older adults (≥65 years) up to 1 month post vaccination.
Submitted to Influenza and other respiratory viruses
04 Apr 2024Submission Checks Completed
04 Apr 2024Assigned to Editor
16 Apr 2024Reviewer(s) Assigned
19 May 2024Review(s) Completed, Editorial Evaluation Pending
26 Jul 2024Editorial Decision: Accept